A new drug application for Finisson tablets by Jingfeng Pharmaceuticals subsidiary has been approved by the U.S. FDA
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, JingfengPharmaceutical(http://announced on the evening of January 1 that its controllingcompany,(http://Sungen Pharma, LLC ("Shangjin") ("Shangjin") received notice from the u.S(http://, and that the joint venture with Tianjin Jinyao Group Co., Ltdin the United States Gene York Pharmaceuticals Group LLC in March 2018 to
the U.Sofhttp:// new drugThe brief application has been approved, meaning that the company is eligible to sell theproduct in the U.Smarket(http://on theof the pernisin tablets It is understood that the tablets are used to treat symptoms such as adrenal cortical degeneration, active rheumatism, rheumatoid arthritis, systemic lupus erythematosusAt present, the main manufacturers in the U.Smarket are Westward, Vintage, Jubilant, Actavis and so onAccording to IMS data, Pernison was sold about $139 million in the U.Smarket in 2017 and $134 million in 2016 and $139 million in 2015
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.